Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 109 UK neurodegenerative disease companies below.
Drug discovery platform targeting biomolecular condensates
Transition Bio is a biotechnology company developing a drug discovery platform based on the biology of biomolecular condensates, the membrane-less cellular structures implicated in a range of diseases. Using droplet microfluidics and machine learning, the company maps and modulates condensate behaviour to identify…
Human iPSC platform for neurodegenerative disease drug discovery
Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease. The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial…
Clinical-stage CNS drug discovery using human brain genomics
Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue…
Patient-derived mitochondrial screening for preclinical drug discovery
Mitotype Precision Labs is a contract research organisation providing patient-derived cellular assays for drug discovery and preclinical evaluation. Its screening services use fibroblasts, neurons and astrocytes to measure mitochondrial function, lysosomal biology and other disease-relevant cellular responses. The…
Full-service CRO delivering UK clinical trials across dedicated research sites
MAC Clinical Research is a contract research organisation conducting Phase I to IV clinical trials for pharmaceutical and biotechnology sponsors. The company operates a fully owned network of dedicated research sites across the UK, including an MHRA accredited Phase I unit, backed by international offices. Services…
Clinical trial delivery for Alzheimer's and neurodegenerative disease
Scottish Brain Sciences is a contract research organisation building and operating clinical trial infrastructure for Alzheimer's disease and other neurodegenerative conditions. Working with pharmaceutical sponsors, it delivers trial screening, patient recruitment, and study conduct at dedicated clinical sites in…
Real-world mental health and dementia data platform for drug development
Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural…
Novel small-molecule therapeutics for neurodegenerative diseases
Nevrargenics is a UK-based biotech company developing novel small-molecule therapeutics for neurodegenerative diseases. Spun out of Durham University and built on research collaboration with the University of Aberdeen, the company uses a patented library of dual-activity retinoic acid receptor modulators designed to…
Multimodal small molecule therapeutics for neurodegenerative disease
Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis. The company's approach targets multiple pathophysiological mechanisms simultaneously,…
C. elegans whole-organism platform for preclinical drug and compound screening
Magnitude Biosciences Limited is a contract research organisation providing preclinical drug discovery and compound screening services using Caenorhabditis elegans as a whole-organism model. Its proprietary biophotonics platform enables automated, high-throughput, non-invasive monitoring of health and lifespan metrics…
Precision medicines targeting protein isoforms for neuromuscular disease
ISOgenix is a biotechnology company developing precision medicines that target disease-relevant protein isoforms for neuromuscular and neurological conditions. The company's approach focuses on identifying and modulating specific isoforms produced through alternative gene splicing and epigenetic regulation, aiming to…
Single-workflow sequencing technology capturing genetic and epigenetic data
biomodal is a Cambridge-based life sciences technology company developing multiomics sequencing solutions that simultaneously capture genetic and epigenetic information from a single DNA sample. Its multiomics platform detects the canonical four DNA bases alongside 5-methylcytosine and 5-hydroxymethylcytosine…
AI-driven neural data platform for bioelectronic medicine
BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation…
Small molecules improving ribosomal translation accuracy in ageing cells
Ribogenyx is a biotechnology company developing small-molecule therapies to improve protein synthesis accuracy in ageing cells. Its approach targets translational fidelity, the accuracy with which ribosomes translate messenger RNA into proteins. By reducing production errors, the company aims to preserve protein…
Single-molecule counting point-of-care diagnostics for cardiac and other biomarkers
Psyros Diagnostics develops a point-of-care diagnostic system using single-molecule counting technology to measure biomarkers at extremely low concentrations within around ten minutes, from a single drop of blood. The platform's lead application is a high-sensitivity troponin assay for cardiac diagnosis, with the…
Specialist CRO for rare disease drug development and commercialisation
TMC Pharma Services is a contract research organisation specialising in drug development support for rare and orphan diseases. The company serves small and mid-sized biotech and biopharma clients across the full development lifecycle, providing regulatory affairs, clinical development, pharmacovigilance, medical…
Convection enhanced delivery consulting and devices for CNS therapeutics
Neurochase is a contract research and consulting organisation specialising in targeted drug delivery to the CNS using convection enhanced delivery. Working with pharmaceutical and biotechnology companies, it designs and optimises delivery strategies for gene therapies and other treatments directed at specific brain…
Contract proteomics CRO and inventor of TMT isobaric mass tags
Proteome Sciences is a contract proteomics organisation and reagent manufacturer specialising in mass spectrometry-based protein biomarker discovery, validation, and targeted assay development. Its proprietary workflows serve pharmaceutical and biotechnology clients across drug discovery and clinical research. The…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company conducts radioligand binding assays, functional GPCR assays, receptor occupancy studies, autoradiography, and surface plasmon resonance using…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…